Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLTANIA Study of olanzapine for prevention of chemotherapy-induced nausea and vomiting in allogeneic hematopoietic stem cell transplantation
jRCT1051260165Recruiting
- Sponsor
- Kasahara Cancer Research Fund
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Kasahara Cancer Research Fund. Primary endpoint: Complete response during the overall period. Started Sep 2026; status: recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT1051260165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051260165.